ArticleAnnals of clinical and translational neurology2026
Uncovering G Protein-Coupled Receptors: Novel Targets and Biomarkers for Predicting Glioma Prognosis.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLow-grade gliomas (LGG) exhibit significant heterogeneity and recurrence risk. G protein-coupled receptors (GPCR) contribute to glioma malignant progression, but their prognostic value remains unclear. This work attempts to formulate a GPCR-based outcome-predicting model for LGG.
methodsBased on TCGA LGG data, the enrichment scores of GPCR genes were calculated via GSVA, and molecular subtypes were recognized through consensus clustering. Hub GPCR genes were screened via weighted gene co-expression network analysis and LASSO regression, enabling the construction of the GPCR index score (GPCRS) model, validated in an independent CGGA cohort. Patients were stratified into high- and low-risk groups accurately for mutation analysis, immune microenvironment assessment, and functional enrichment analysis, comprehensively elucidating the clinical significance of the GPCRS model.
resultsLGG was classified into two subtypes based on GPCR-related gene expression. Using WGCNA and machine learning, nine hub GPCR genes (SSTR2, GPR61, SSTR1, OR2H2, CHRM4, P2RY2, GPR63, OPN3, GRPR) were identified. The GPCRS model effectively predicted prognosis, with area under the curve values for 1-, 3-, and 5-year overall survival, respectively, above 0.78, 0.72, and 0.71. Functional enrichment and immune analyses showed that the high-risk group is enriched in embryonic development and cytokine-related pathways, with a more complex immune microenvironment. Whereas the low-risk group is focused on GPCR signaling and neuro-related processes. Mutation analysis revealed differences in mutation profiles and co-mutation patterns between risk groups.
conclusionThe GPCRS model serves as a reliable prognostic biomarker, providing insights into LGG molecular subtyping and potential targets for precision therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.